Comorbidity in newly diagnosed thyroid cancer patients: a population-based study on prevalence and the impact on treatment and survival - PubMed (original) (raw)
Comorbidity in newly diagnosed thyroid cancer patients: a population-based study on prevalence and the impact on treatment and survival
Johannes L P Kuijpens et al. Clin Endocrinol (Oxf). 2006 Apr.
Abstract
Background: Comorbidity may be an important contributory factor to differences in the treatment and outcome of cancer, especially in older patients. It might also provide information on the aetiology of the cancer in cases of high or low frequency. The aim of this study was to describe the spectrum of comorbidity and the possible impact on treatment and survival in newly diagnosed thyroid cancer (TC).
Design: A population-based observational study.
Setting: The Eindhoven Cancer Registry, Comprehensive Cancer Centre South (IKZ), the Netherlands.
Methods: Demographic, histological and treatment data on all 417 TC patients diagnosed between 1 January 1993 and 31 December 2002 were collected and followed up till 2004. An adapted version of the list of Charlson was used for registration of clinically relevant concomitant disorders. The prevalence of comorbidity at diagnosis was analysed according to gender, age, histological type and therapy. Crude 6-month and 1- and 5-year survival rates were determined. A regression analysis was performed to identify independent variables related to survival.
Results: Information on comorbidity was available for 378 patients (91%). Comorbidity was present in 32% of the patients; 23% had one and 12% had two or more concomitant diseases. The prevalence of comorbidity increased with age. Hypertension was the most frequent comorbidity (18%), followed by 'other cancers' (7%), cardiovascular diseases (6%) and diabetes mellitus (6%). The prevalence of hypertension was twice as high as expected at all age groups. Six patients > 60 years had had tuberculosis. Initial surgical treatment was negatively related to the presence of concomitant diseases in patients < 70 years (P = 0.02), but not in patients > or = 70 years. Comorbidity was not independently associated with crude survival up to 5 years.
Conclusions: A previous diagnosis of hypertension was associated with TC. The use of external radiation for diagnostic and therapeutic procedures for tuberculosis probably explains the high prevalence of former tuberculosis in elderly TC patients. Treatment choices appeared to be influenced by the presence of comorbidity. Comorbidity did not affect survival up to 5 years; a study with a longer period of follow-up is needed.
Similar articles
- Changing trends in incidence and mortality of thyroid cancer in Scotland.
Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW. Reynolds RM, et al. Clin Endocrinol (Oxf). 2005 Feb;62(2):156-62. doi: 10.1111/j.1365-2265.2004.02187.x. Clin Endocrinol (Oxf). 2005. PMID: 15670190 - [Thyroid cancer in Southeastern Netherlands, 1970-1989: trends in incidence, treatment and survival].
Kuijpens JL, Coebergh JW, van der Heijden LH, Kruis H, Ribot JG, de Rooij HA. Kuijpens JL, et al. Ned Tijdschr Geneeskd. 1994 Feb 26;138(9):464-8. Ned Tijdschr Geneeskd. 1994. PMID: 8133948 Dutch. - [The effect of gender on prevalence and survival in thyroid carcinoma].
Nĕmec J, Chytrý P, Dvorák J, Vlcek P, Neradilová M, Racek P, Blazek T, Zeman V. Nĕmec J, et al. Vnitr Lek. 1996 Sep;42(9):602-4. Vnitr Lek. 1996. PMID: 8984765 Czech. - [Classification and epidemiology of thyroid tumors].
Klein M, Aubert V, Weryha G, Leclère J. Klein M, et al. Rev Prat. 1996 Dec 1;46(19):2288-95. Rev Prat. 1996. PMID: 8978185 Review. French. - [Malignant thyroid tumors in Hungary: morbidity and mortality].
Esik O, Szentirmay Z, Tusnády G, Németh G, Kásler M. Esik O, et al. Orv Hetil. 1996 Apr 28;137(17):905-11. Orv Hetil. 1996. PMID: 8649753 Review. Hungarian.
Cited by
- Consumption of health resources in older people with differentiated thyroid carcinoma: a multicenter analysis.
Díez JJ, Anda E, Alcazar V, Isidro ML, Familiar C, Paja M, Martín Rojas-Marcos P, Pérez-Corral B, Navarro E, Romero-Lluch AR, Oleaga A, Pamplona MJ, Fernández-García JC, Megía A, Manjón-Miguélez L, Sánchez-Ragnarsson C, Iglesias P, Sastre J. Díez JJ, et al. Endocrine. 2023 Sep;81(3):521-531. doi: 10.1007/s12020-023-03369-9. Epub 2023 Apr 27. Endocrine. 2023. PMID: 37103683 - Metabolic and cardiovascular risk in patients with a history of differentiated thyroid carcinoma: A case-controlled cohort study.
Giusti M, Mortara L, Degrandi R, Cecoli F, Mussap M, Rodriguez G, Ferone D, Minuto F. Giusti M, et al. Thyroid Res. 2008 Sep 29;1(1):2. doi: 10.1186/1756-6614-1-2. Thyroid Res. 2008. PMID: 19014658 Free PMC article. - Development of a New Clinical Severity Staging System for Patients With Nonmetastatic Papillary Thyroid Carcinoma.
Karadaghy OA, Kallogjeri D, Piccirillo JF. Karadaghy OA, et al. JAMA Otolaryngol Head Neck Surg. 2017 Dec 1;143(12):1173-1180. doi: 10.1001/jamaoto.2017.0550. JAMA Otolaryngol Head Neck Surg. 2017. PMID: 28449113 Free PMC article. - REFERRAL OF OLDER THYROID CANCER PATIENTS TO A HIGH-VOLUME SURGEON: RESULTS OF A MULTIDISCIPLINARY PHYSICIAN SURVEY.
Papaleontiou M, Gauger PG, Haymart MR. Papaleontiou M, et al. Endocr Pract. 2017 Jul;23(7):808-815. doi: 10.4158/EP171788.OR. Epub 2017 May 23. Endocr Pract. 2017. PMID: 28534681 Free PMC article. - Long-term all-cause mortality and its association with cardiovascular risk factors in thyroid cancer survivors: an Israeli population-based study.
Izkhakov E, Keinan-Boker L, Barchana M, Shacham Y, Yaish I, Carmel Neiderman NN, Fliss DM, Stern N, Meyerovitch J. Izkhakov E, et al. BMC Cancer. 2020 Sep 17;20(1):892. doi: 10.1186/s12885-020-07401-3. BMC Cancer. 2020. PMID: 32942995 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical